Last updated on September 2018

Study of BTK Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenstr m's Macroglobulinemia (WM)


Brief description of study

Screening (up to 28 days); daily treatment until disease progression, unacceptable toxicity or death, withdrawal of consent, lost to follow-up, or study termination from sponsor; treatment (up to 3 years), safety follow up (28 days); survival follow-up until data cutoff for final analysis.

Clinical Study Identifier: NCT03332173

Contact Investigators or Research Sites near you

Start Over

Meng Ji

The first affiliated hospital of Soochow University
Suzhou, China
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.